Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Post by AlbertOyleron Oct 21, 2018 9:51am
387 Views
Post# 28842913

Some Sunday reading

Some Sunday readingHow about that glossy Scotiabank publication on 'initiating coverage on Aphria'. Aphria being undervalued and Canopy being fully valued. Lots of interesting developments.

In my opinion, Aphria’s strong fundamentals and unique partnerships reflect something more than just a competitive advantage. It shows management’s ability to navigate this market with finesse. This pragmatic leadership style should help the company live up to its own ambitions and true potential.
Vishesh Raisinghani | October 21, 2018 Motley Fool
https://www.fool.ca/2018/10/21/can-aphria-inc-tsxaph-live-up-to-its-true-potential/


We have initiated coverage on Aphria Inc. with a Sector Outperform rating, a target price of $25.00 per share, and a bear-to-bull range of $15 to $34. Aphria is building one of the largest cannabis production platforms in Canada and internationally. The company is not trying to be all things to all people; rather, it intends to focus on perfecting large-scale production economics to generate high industry margins in the Canadian medical and recreational markets. We value Aphria by applying a 15x EV/EBITDA multiple to out-year achievable EBITDA of $450 million, ~40% of which is theoretical and based on likely funding capabilities. We think Aphria is the best way to play the cannabis space in our limited coverage universe.
https://advisor.scotiawealthmanagement.com/content/uploads/sites/214/Marijuana-Analyst-Report.pdf
Scotiabank October 2018
 
 Aphria Inc (OTCMKTS:APHQF) remains one our favorites primarily because it likely has some interesting catalysts ahead. It’s plausible to imagine the stock following Aurora over to the NYSE, and being quite attractive to major players for a possible strategic deal (such as the Altria rumors we saw two weeks ago). In addition, the company recently announced that it has formed an alliance with noted UK-based neurologist and rehabilitation physician Professor Michael Barnes MD FRCP, a leading voice on medical cannabis policy in Europe.
 October 20, 2018
By
 Brandon Manns
https://mmjreporter.com/expansion-continues-for-aphria-inc-otcmktsaphqf-with-strong-catalysts-likely-ahead/
mmjreporter
 

 
Bullboard Posts